Skip to main content

Peer Review reports

From: Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination

Original Submission
24 Feb 2022 Submitted Original manuscript
4 Mar 2022 Reviewed Reviewer Report
10 Mar 2022 Reviewed Reviewer Report - Ling-xiao Liu
17 Mar 2022 Author responded Author comments - Bin Xiong
Resubmission - Version 2
17 Mar 2022 Submitted Manuscript version 2
22 Mar 2022 Editorially accepted
27 Mar 2022 Article published 10.1186/s12885-022-09451-1

You can find further information about peer review here.

Back to article page